D e s i g n
Two* randomized (allocation concealed †), blinded {patients, clinicians, data collectors, outcome assessors, data analysts, and manuscript writers} ‡, † placebo-controlled trials with mean follow-up of 3.9 years (Perindopril Protection against Recurrent Stroke Study [PROGRESS]).
S e t t i n g
172 centers from 10 countries.
P a t i e n t s
6105 patients (mean age 64 y, 70% men) who had a history of stroke or TIA in the previous 5 years, had no definite indication for or contraindication to an angiotensinconverting enzyme (ACE) inhibitor, and were clinically stable for ≥ 2 weeks after their most recent vascular event. 6102 patients (> 99%) completed follow-up for fatal events.
I n t e r v e n t i o n
Some patients were allocated to perindopril, 4 mg daily (n = 1281), or to single placebo (n = 1280). Other patients, for whom the responsible physician found no specific indication for or contraindication to a diuretic, were allocated to perindopril plus indapamide (indapamide dose 2.0 or 2.5 mg daily) (n = 1770) or to double placebo (n = 1774).
M a i n o u t c o m e m e a s u r e s
Fatal or nonfatal stroke. Secondary outcomes included fatal or disabling stroke with the disability defined at the first scheduled follow-up visit after the event and a composite vascular end point of nonfatal stroke, nonfatal myocardial infarction, or death from any vascular cause.
M a i n r e s u l t s
Analysis was by intention to treat. Patients who received perindopril and indapamide had greater reductions in blood pressure and in stroke, stroke subtypes, and vascular events than did patients who received double placebo (P < 0.001) (Table) . Perindopril alone showed no more reduction in stroke or major vascular events than did single placebo (Table) . The relative effects of combination therapy did not differ in patients with and without a pre-existing diagnosis of hypertension.
C o n c l u s i o n s
In patients with a history of stroke or transient ischemic attack, treatment with indapamide and perindopril was more effective than treatment with placebo for reducing fatal or nonfatal stroke. Treatment with perindopril alone was not effective. C o m m e n t a r y PROGRESS contains 2 distinct trials. The combination of perindopril and indapamide showed large and consistent benefits; perindopril alone did not. The results of the 2 trials should not be combined or even compared: The patients differed in age, blood pressure, and other features, and the results were heterogeneous. The results of PROGRESS cannot tell us whether the benefits of combination therapy were from indapamide alone or from the combination of indapamide and perindopril. Support for a diuretic monotherapy effect comes from other studies, including the Post-stroke Antihypertensive Treatment Study (1) , in which indapamide alone (vs placebo) showed a 29% relative reduction (P = 0.0013) in stroke recurrence. No single diuretic has been shown to be superior to any other diuretic. Stroke results for other ACE inhibitors are mixed and include the Heart Outcomes Prevention Evaluation (HOPE) trial (2), in which ramipril showed greater reductions than placebo, and the Captopril Prevention Project trial (3), in which captopril showed an increased risk for stroke over that with diuretics or β-blockers, or both. PROGRESS suggests that all stroke patients, regardless of hypertensive status, should be treated with a diuretic. Adding an ACE inhibitor can be considered on the basis of the large effect of combination therapy in PROGRESS or in the HOPE trial, but it has not been proved to give additional protection; direct comparisons of diuretics and diuretics plus ACE inhibitors are lacking. Furthermore, evidence continues to grow that patients with ischemic stroke should be treated with some form of antithrombotic therapy and a coenzyme A reductase inhibitor (statin).
David 
